Recombinant benefits win out

Recombinant benefits win out

BETHESDA, Md. - The safety benefits inherent in a recombinant product persuaded members of the FDA's Blood Products Advisory Committee last week to recommend approval of Genetic Institute Inc.'s BeneFix Coagulation Factor IX to treat hemophilia B despite concerns about the small number of patients involved in GENIZ's trials and indications that BeneFix is less potent than the

Read the full 620 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE